

## News Release

## Alcentra Announces Successful Completion of \$245m Unitranche Investment in Lumenis for XIO Group

LONDON, 06 October 2016 – Alcentra Limited announced today that it has provided a \$245m unitranche facility to Lumenis to refinance its existing debt and rebalance its capital structure.

Founded in 1991, Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercialising innovative energy-based technologies.

Over the last 3 years Lumenis has successfully evolved its strategy, introduced new products, and doubled its EBITDA whilst enhancing its global brand recognition. The Company is well positioned for further growth having built a robust pipeline of innovative products.

XIO Group is an alternative investment firm headquartered in London, with operations in Europe, Hong Kong and China. XIO Group's strategy is to identify and invest in market-leading businesses located across North America and Europe and to assist these companies in capitalising on untapped opportunities in high growth markets, particularly in Asia.

Jens-Dino Steinborn, Executive Director at XIO Group, said: "We chose to work with Alcentra because they were able to deliver a flexible and bespoke solution that supports the expansion strategy of the business. We look forward to developing our relationship with Alcentra going forward".

Natalia Tsitoura, Managing Director within Alcentra's European Direct Lending and Mezzanine Investments Team, said: "We are very pleased to provide financing to Lumenis. The business has performed well in the last few years and has a clear strategy for sustained international growth. Lumenis is led by a very strong management team and holds leading positions in high growth markets. We are also delighted to complete our first transaction with XIO Group".

XIO Group were advised by Fried, Frank, Harris, Shriver & Jacobson LLP and Erdinast, Ben Nathan, Toledano & Co (Legal) and PricewaterhouseCoopers (Tax), with Jones Day acting as international counsel. Linklaters acted for Alcentra.

-ends-

## About Alcentra:

**Alcentra Group** is a global asset management firm with assets under management of approximately \$29 billion <sup>1</sup>, Alcentra Group has an investment track record that dates back to 1998. Strategies include: senior loans, high yield bonds, direct lending, structured credit, distressed debt, and multi-strategy credit. Alcentra Group is owned by The Bank of New York Mellon Corporation and is headquartered in London, with offices in New York and Boston. Please visit our website at <u>www.alcentra.com</u> for more information.

<sup>1</sup> Alcentra Ltd and Alcentra NY, LLC (collectively "Alcentra Group") are subsidiaries of BNY Alcentra Group Holdings Inc. The Bank of New York Mellon Corporation ("BNY Mellon") holds 100% of the Alcentra Group. Assets under management reflect assets of all accounts and portions of accounts managed by Alcentra Group for Alcentra Group and its affiliates. Specifically, certain assets under management reflect assets managed by Alcentra Group



personnel as employees of Standish Mellon Asset Management ("Standish"), BNY Mellon and/or The Dreyfus Corporation ("Dreyfus") under a dual employee arrangement. BNY Mellon is not a guarantor of any investment managed by Alcentra.

This news release is qualified for issuance in the UK, Europe and US and is for information purposes only. It does not constitute an offer or solicitation of securities or investment services or an endorsement thereof in any jurisdiction or in any circumstance in which such offer or solicitation is unlawful or not authorized. Any views and opinions contained in this document are those of the investment manager, unless otherwise noted. This news release is issued by Alcentra Limited, 10 Gresham Street, London EC2V 7JD Authorised and Regulated by the Financial Conduct Authority to members of the financial press and media and the information contained herein should not be construed as investment advice. Past performance is not a guide to future performance.